Delayed treatment with 5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione, a glycine site N-methyl-D-aspartate antagonist, protects against permanent middle cerebral artery occlusion in male rats

Neuroscience Letters

Volumn 347, Issue 3, 2003, Pages 147-150

  Sarhan, Shakir ^a   Wettstein, Joseph G ^a   Maynard, Kenneth I ^a  

^a SANOFI   (France)

Author keywords

Fischer 344 rats; Focal cerebral ischemia; Infarction; Neuroprotection; Nicotinamide; Sprague Dawley rats; Stroke

Indexed keywords

6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINAMIDE; GLYCINE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL PROTECTION; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; EXPERIMENTAL TEST; INJECTION; MALE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT STRAIN; STROKE; ANIMAL; BRAIN; CEREBRAL ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; FISCHER 344 RAT; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; RAT; TIME;

ANIMALS; BRAIN; BRAIN INFARCTION; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; MALE; NEUROPROTECTIVE AGENTS; QUINOXALINES; RATS; RATS, INBRED F344; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 0042090215     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00693-1     Document Type: Article

References (20)

1. Ayoub I.A., Lee E.J., Ogilvy C.S., Beal M.F., Maynard K.I. Nicotinamide reduces infarction up to 2 h after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci. Lett. 259:1999;21-24.
2. Beardsley P.M., Ratti E., Balster R.L., Willetts J., Trist D. The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects. Behav. Pharmacol. 13:2002;583-592.
3. Belayev L., Alonso O.F., Busto R., Zhao W., Ginsberg M.D. Middle cerebral artery occlusion in the rat by intraluminal suture. Stroke. 27:1996;1616-1623.
4. Benveniste H., Drejer J., Schousboe A., Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43:1984;1369-1374.
5. Buchan A.M. Do NMDA antagonists protect against cerebral ischemia; are clinical trials warranted? Cerebrovasc. Brain Metab. Rev. 2:1990;1-26.
6. 2+-dependent modification of the N-methyl-D-aspartate receptor following graded hypoxia in the cerebral cortex of newborn piglets. Neuroscience. 92:1999;685-692.
7. Hatfried R.H., Gill R., Brazell C. The dose-response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model. Eur. J. Pharmacol. 216:1992;1-7.
8. Meldrum B.S. Cytoprotective therapies in stroke. Curr. Opin. Neurol. 8:1995;15-23.
9. Nishizawa Y. Glutamate release and neuronal damage in ischemia. Life Sci. 69:2001;369-381.
10. Novellii A., Reilly A.J., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451:1988;205-212.
11. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. 24:1988;543-551.
12. Sacco R.L., DeRosa J.T., Haley E.C. Jr., Levin B., Ordronneau P., Phillips S.J., Rundek T., Snipes R.G., Thompson J.L. Glycine antagonists in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. J. Am. Med. Assoc. 285:2001;1719-1728.
13. Sakakibara Y., Mitha A.P., Ayoub I.A., Ogilvy C.S., Maynard K.I. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res. 931:2002;68-73.
14. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semi-automated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10:1990;290-293.
15. Takaoka S., Bart R.D., Pearlstein R., Brinkhous A., Warner D.S. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. J. Cereb. Blood Flow Metab. 17:1997;161-167.
16. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischemia in the rat. 1. Description of technique and early neurological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;53-60.
17. Tsuchida E., Bullock R. The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on brain ischemic brain damage caused by acute subdural hematoma in the rat. J. Neurotrauma. 12:1995;279-288.
18. Warner D.S., Martin H., Ludwig P., McAllister A., Keana J.F.W., Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15:1995;188-196.
19. Woodward R.M., Huettner J.E., Guastella J., Keana J.F., Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sides. Mol. Pharmacol. 47:1995;568-581.
20. Zeevalk G.D., Nicklas W.J. Mechanisms underlying inhibition of excitotoxicity associated with metabolic inhibition. J. Pharmacol. Exp. Ther. 257:1991;870-878.